- Home
- XP vs BBIO Comparison
XP vs BBIO Comparison
Compare XP & BBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XP
- BBIO
- Stock Information
- Founded
- XP 2001
- BBIO 2015
- Country
- XP Cayman Islands
- BBIO United States
- Employees
- XP N/A
- BBIO N/A
- Industry
- XP Investment Bankers/Brokers/Service
- BBIO Biotechnology: Pharmaceutical Preparations
- Sector
- XP Finance
- BBIO Health Care
- Exchange
- XP Nasdaq
- BBIO Nasdaq
- Market Cap
- XP 9.8B
- BBIO 9.4B
- IPO Year
- XP 2019
- BBIO 2019
- Fundamental
- Price
- XP $18.91
- BBIO $53.38
- Analyst Decision
- XP Strong Buy
- BBIO Strong Buy
- Analyst Count
- XP 5
- BBIO 16
- Target Price
- XP $23.80
- BBIO $63.81
- AVG Volume (30 Days)
- XP 6.8M
- BBIO 2.3M
- Earning Date
- XP 08-18-2025
- BBIO 08-05-2025
- Dividend Yield
- XP 7.29%
- BBIO N/A
- EPS Growth
- XP 18.07
- BBIO N/A
- EPS
- XP 1.67
- BBIO N/A
- Revenue
- XP $3,085,301,717.00
- BBIO $235,812,000.00
- Revenue This Year
- XP $18.06
- BBIO $115.49
- Revenue Next Year
- XP $12.97
- BBIO $64.61
- P/E Ratio
- XP $10.71
- BBIO N/A
- Revenue Growth
- XP 6.65
- BBIO 7.62
- 52 Week Low
- XP $10.82
- BBIO $21.72
- 52 Week High
- XP $20.64
- BBIO $53.97
- Technical
- Relative Strength Index (RSI)
- XP 64.80
- BBIO 63.37
- Support Level
- XP $17.55
- BBIO $49.75
- Resistance Level
- XP $18.07
- BBIO $52.85
- Average True Range (ATR)
- XP 0.54
- BBIO 2.12
- MACD
- XP 0.23
- BBIO 0.18
- Stochastic Oscillator
- XP 99.69
- BBIO 91.76
About XP XP Inc.
XP Inc is a Cayman Island-based technology-driven financial services platform. It is a provider of low-fee financial products and services in Brazil. The company evaluates its business through a single segment such as monitoring operations, making decisions on fund allocation, and evaluating the performance. It generates revenue through the Brokerage commission.
About BBIO BridgeBio Pharma Inc.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.